This content was created by Everyday Health Media on behalf of an advertiser.
More Information.
Content on this page was created by the Everyday Health Media team and is funded by an advertiser. The content conforms to Everyday Health Media’s editorial standards for accuracy, objectivity, and balance. The advertiser may select the specialty area but does not edit or approve the content.
Chronic Lymphocytic Leukemia Peer-to-Peer
PSA: EVOLVE CLL Study
Brian Hill, MD, PhD, of Cleveland Clinic, discusses the EVOLVE CLL early intervention trial, which may be worth considering for high-risk patients. (1:30)
Lymphoma Type May Affect Response to COVID Vaccination
The subtype of lymphoma and the timing of anticancer treatment was shown to directly affect the level of seroconversion in cancer patients administered COVID vaccination.
Chronic Lymphocytic Leukemia: A Closer Look at Clonal Cell Subpopulations
A recent study, led by a team of investigators based in the U.K., took on the task of identifying proliferative and nonproliferative subpopulations of leukemic cells in chronic lymphocytic lymphoma.
Richter’s Transformation in CLL: What are the Risk Factors?
Richter's transformation in patients on active surveillance is very rare, explains Brian Hill, MD, PhD, of Cleveland Clinic. While it's hard to quantify, it appears that prior treatment with treatment resistance is one possible risk factor. (2:00)
Leukemias and Multiple Myeloma: Building Better Studies
Findings from clinical trials for drugs to treat leukemias and multiple myeloma may not accurately represent the people who are most at risk for these diseases, because of limited participation by certain populations. That’s a design flaw that needs to be addressed as soon as possible, experts say.
video
Molecular Testing in CLL
Q&A: Do CLL Patients Benefit from High-Intensity Interval Training? Resistance Training?
Duke University investigators spoke to us about the effects of high-intensity interval training and resistance training on health-related quality of life in patients with CLL.
COVID-19 Vaccinations in Patients with Hematologic Malignancies
A 3-dose schedule or a 2-dose schedule? That question was at the core of a recent study that examined the efficacy of mRNA-1273 SARS-CoV-2 vaccination in immunocompromised patients with hematologic cancers.
In CLL, Do These Biomarkers Tell a Story About Physical Fitness and Function?
Specific clinical factors, such as treatment status and disease duration, along with certain lipid and lipoprotein levels seem to be associated with physical performance and fitness levels in patients with CLL.
TP53 Gene Mutational Status Among Patients with CLL
Using next-generation sequencing, a team of investigators retrospectively studied rates of TP53 mutations among patients with chronic lymphocytic leukemia. Some of the findings suggest that detection of subclonal TP53 mutations may change treatment.
Do Statins Improve Survival in Patients with Lymphoma?
Statins don’t significantly reduce mortality from lymphoma specifically, but rather protect against death from cardiovascular complications and other causes, a new study has concluded.
Q&A: CLL Prognostic Models
Lindsey Roeker, MD, of Memorial Sloan Kettering Cancer Center, answers our questions about prognostication in chronic lymphocytic leukemia and how it may evolve to improve outcomes, not just risk prediction.
CLL and Atrial Fibrillation: The Burden on Hospitalized Patients
Atrial fibrillation (AF), a recognized complication in patients being treated for chronic lymphocytic leukemia (CLL), deserves much wider attention in the cardio-oncology community, suggest the results of a new study. Here’s why.
CLL: Tracking a Marker of Progression
Monoclonal B-cell lymphocytosis (MBL) is known to predict chronic lymphocytic leukemia risk in certain individuals. But a new study finds that relatives of patients with MBL—either low count or high count—can be at higher risk for CLL, too.
Chronic Lymphocytic Leukemia: What Families Can Tell Us
Chronic lymphocytic leukemia is the most common type of leukemia in adults, but establishing which variables drive it has been difficult. A new study looked at genetic patterns among families with CLL for answers.
Q&A With Lindsey Roeker, MD: CLL and COVID-19 vaccine
Dr. Roeker describes what is known today about the antibody response rates to COVID-19 vaccination among patients with CLL—and what remains to be learned.
CLL and NHL Linked to Certain Skin Traits
French researchers recently examined associations among pigmentary traits, sun exposure, and risk of non-Hodgkin lymphoma and chronic lymphocytic leukemia.
CLL Patients Show Low Response to COVID-19 Vaccine, But Does Remission Improve Immunity?
Patients with chronic lymphocytic leukemia are at greater risk of severe disease and mortality with COVID-19 infection, and a recent study shows impaired response to vaccination, particularly among patients on active treatment.
Concordance of Leukemia Outcomes Among First-Degree Relatives
Swedish investigators analyzed patient data spanning more than 50 years to get a sense of how patterns of survival are affected when patients and a first-degree relative suffer from the same type of indolent lymphoid malignancy.
In CLL: The Association of Survival and Gammaglobulin Abnormalities
Researchers studied whether levels and type of Ig monoclonal gammopathy have significance in terms of survival and on clinical and biological features in chronic lymphocytic leukemia.
Hematological Malignancies and Pneumococcal Disease Risk
A population-based study from Denmark showed a higher incidence of pneumococcal disease in adults with hematological malignancies, confirming that more effort to prevent this infection is warranted.